<DOC>
	<DOCNO>NCT01218919</DOCNO>
	<brief_summary>The objective study evaluate effectiveness rechargeable Deep Brain Stimulation adjunctive treatment reduce symptom advance , levodopa-responsive Parkinson 's disease adequately controlled medication . This first observational study use BRIO™ rechargeable constant current device , use lead active electrode tip deep brain stimulation Parkinson subject . The current study design conform normal medical practice , take consideration current day economic constraint , assess best set circumstance successful sustain reduction symptom advance , levodopa-responsive Parkinson 's disease adequately controlled medication .</brief_summary>
	<brief_title>Post Market ( Brio™ System ) Deep Brain Stimulation ( DBS ) PD Study</brief_title>
	<detailed_description>This study design prospective , observational , non-randomized , multi-centered study total 10 year duration . It 10 year study system implantation activation yearly database lock report , subject use control . The primary outcome assessment occur three month . Following completion primary outcome assessment , patient annual visit 10 year post implant . Comparison measure within person pre-treatment post-treatment performed . During implantation procedure , subject undergo trial stimulation operate room among potential assessment determine proper lead placement . The device may internalize successful intra-operative trial later date accord investigator site practice . The date component implant programmed classified `` Day 0 '' . After system activation subject return clinic post-operative evaluation 1 month ( +/-14 day ) , 3 month ( +/-14 day ) , 6 month ( +/-14 day ) 12 month ( +/-30 day ) . Thereafter , long term data collection program follow 10 year post-implant .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Subject sign informed consent . 2 . Subject diagnose , neurologist , idiopathic Parkinson 's disease . 3 . Subject candidate surgery . 4 . Subject 18 80 year age . 5 . Subject history improvement Parkinson 's symptom direct result administer Ldopa subject least 25 % improvement UPDRS motor score subject diagnose tremordominant Parkinson 's disease . 6 . Subject stable antiParkinson 's disease medication least one month prior study enrollment 1 . Subject major illness medical condition opinion physician would interfere participation study . 2 . Subject nontreated clinically significant depression significant psychiatric comorbidities . 3 . Subject condition require repeat MRI scan ; 4 . Subject anticoagulant medication unable interrupt time procedure . 5 . Subject dementia interfere ability cooperate comply study requirement comprehend Informed Consent determine investigator . 6 . Subject abuse drug alcohol . 7 . Subject history seizure ( Neurosurgeon must approve ) 8 . Subject confirmation diagnosis terminal illness associate survival &lt; 12 month . 9 . Female lactate childbearing potential positive urine pregnancy test use adequate birth control . 10 . Subject participated drug , device biological trial within precede 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>